Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by Monashee Investment Management LLC

Monashee Investment Management LLC reduced its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 17.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 132,000 shares of the company’s stock after selling 27,608 shares during the quarter. Structure Therapeutics comprises approximately 0.5% of Monashee Investment Management LLC’s portfolio, making the stock its 19th biggest position. Monashee Investment Management LLC’s holdings in Structure Therapeutics were worth $3,580,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. State Street Corp increased its stake in shares of Structure Therapeutics by 27.0% during the third quarter. State Street Corp now owns 12,295 shares of the company’s stock worth $540,000 after acquiring an additional 2,611 shares during the period. Barclays PLC grew its stake in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after acquiring an additional 31,815 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after purchasing an additional 312 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Structure Therapeutics by 9.4% in the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company’s stock worth $30,991,000 after acquiring an additional 60,397 shares during the last quarter. Finally, Exome Asset Management LLC acquired a new position in Structure Therapeutics in the 3rd quarter valued at about $5,274,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

GPCR stock opened at $25.91 on Wednesday. The company’s 50 day simple moving average is $20.21 and its 200-day simple moving average is $27.59. Structure Therapeutics Inc. has a 52-week low of $13.22 and a 52-week high of $62.74. The firm has a market capitalization of $1.49 billion, a P/E ratio of -35.01 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sell-side analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on GPCR. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and a consensus target price of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.